"The US Food and Drug Administration (FDA) has approved lenvatinib (Lenvima, Eisai), in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma who were previously treated with an anti-angiogenic ther"...
VOTRIENT® is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
Limitation Of Use
The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.
DOSAGE AND ADMINISTRATION
The recommended starting dose of VOTRIENT is 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal) [see CLINICAL PHARMACOLOGY]. The dose of VOTRIENT should not exceed 800 mg.
Do not crush tablets due to the potential for increased rate of absorption which may affect systemic exposure [see CLINICAL PHARMACOLOGY].
If a dose is missed, it should not be taken if it is less than 12 hours until the next dose.
Dose Modification Guidelines
In RCC, the initial dose reduction should be 400 mg, and additional dose decrease or increase should be in 200-mg steps based on individual tolerability.
In STS, a decrease or increase should be in 200-mg steps based on individual tolerability.
No dose adjustment is required in patients with mild hepatic impairment. In patients with moderate hepatic impairment, alternatives to VOTRIENT should be considered. If VOTRIENT is used in patients with moderate hepatic impairment, the dose should be reduced to 200 mg per day. VOTRIENT is not recommended in patients with severe hepatic impairment [see Use in Specific Populations, CLINICAL PHARMACOLOGY].
Concomitant Strong CYP3A4 Inhibitors
The concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) increases pazopanib concentrations and should be avoided. Consider an alternate concomitant medication with no or minimal potential to inhibit CYP3A4. If coadministration of a strong CYP3A4 inhibitor is warranted, reduce the dose of VOTRIENT to 400 mg. Further dose reductions may be needed if adverse effects occur during therapy [see DRUG INTERACTIONS, CLINICAL PHARMACOLOGY].
Concomitant Strong CYP3A4 Inducer
The concomitant use of strong CYP3A4 inducers (e.g., rifampin) may decrease pazopanib concentrations and should be avoided. Consider an alternate concomitant medication with no or minimal enzyme induction potential. VOTRIENT should not be used in patients who cannot avoid chronic use of strong CYP3A4 inducers [see DRUG INTERACTIONS].
Dosage Forms And Strengths
200-mg tablets of VOTRIENT — modified capsule-shaped, gray, film-coated with GS JT debossed on one side. Each tablet contains 216.7 mg of pazopanib hydrochloride equivalent to 200 mg of pazopanib.
Storage And Handling
The 200-mg tablets of VOTRIENT are modified capsule-shaped, gray, film-coated with GS JT debossed on one side and are available in:
Bottles of 120 tablets: NDC 0173-0804-09
Store at room temperature between 20°C and 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
GlaxoSmithKline, Research Triangle Park, NC 27709. Revised: May 2016This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 6/6/2016
Additional Votrient Information
Votrient - User Reviews
Votrient User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.